They found that <50% of patients had return to baseline in erectile function with or without PDE-5 use post RRPX; 22% had return to baseline if they did not use PDE-5 inhibitors. These rates are significantly lower than in the literature and patients should be counseled regarding the significant risk of the lack of return to baseline in erectile function.
Presented by P. Scardino, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA
Reported for UroToday by Pamela Ellsworth, MD, Associate Professor of Urology/Surgery and Pediatrics at the Warren Alpert Medical School at Brown University, Providence, Rhode Island.
View Full AUA 2011 Meeting Coverage